BEST OF HEMATOLOGY 2024: Hodgkin’s Lymphoma – Dr. Erma Gardner
OR
Chair
Dr. Martina Trinkaus
Dr. Matthew Seftel
Panelist
Dr. Erma Gardner
Studies/trials discussed:
- Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients
- The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma
- The Role of Radiotherapy in Hodgkin’s Lymphoma: What Has Been Achieved during the Last 50 Years?
- Hodgkin lymphoma treatment for older persons in the modern era
- Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial
- The biology and management of systemic anaplastic large cell lymphoma
- Management of limited-stage Hodgkin lymphoma
- Immune-checkpoint inhibitors: long-term implications of toxicity
- Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
- Five-year follow-up of KEYNOTE-087:pembrolizumab monotherapy for relapsed/refractory
- classical Hodgkin lymphoma
- Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies
- Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study
- The optimal management of relapsed and refractory Hodgkin lymphoma: post–brentuximab and checkpoint inhibitor failure
- Inferior outcomes and treatment disparities in elderly patients with classical Hodgkin lymphoma: a national cancer data base analysis
- A simplified frailty score predicts survival and can aid treatment-intensity decisions in older patients with DLBCL
- The DLBCL90 gene-expression assay identifies double-hit lymphomas with high sensitivity in patients from two phase II clinical trials with high-risk diffuse large B-cell lymphoma
- Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi
- Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial
- Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi
- How I manage mantle cell lymphoma: indolent versus aggressive disease
- ‘ACOPP’ chemotherapy for older and less fit patients with Hodgkin lymphoma—A multicentre, retrospective study
